Altimmune Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
ALT$1.94-8.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| | |
|---|---|
| Report of Independent Registered Public Accounting Firm — Ernst & Young LLP (PCAOB ID: 42) | 97 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | 99 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 | 100 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023 and 2022 | 101 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | 102 |
| Notes to Consolidated Financial Statements | 103 |
| 1. Nature of Business and Organization | 103 |
| 2. Summary of Significant Accounting Policies | 103 |
| 3. Fair Value Measurement | 109 |
| 4. Property and Equipment, Net | 111 |
| 5. Leases | 111 |
| 6. Accrued Expenses and Other Current Liabilities | 112 |
| 7. Noncurrent Liabilities | 112 |
| 8. Common Stock | 112 |
| 9. Warrants | 114 |
| 10. Stock-Based Compensation | 114 |
| 11. Employee Benefit Plans | 117 |
| 12. Income Taxes | 117 |
| 13. Net Loss Per Share | 119 |
| 14. Commitments and Contingencies | 120 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.